Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease

J Dermatolog Treat. 2021 Mar;32(2):261-263. doi: 10.1080/09546634.2019.1654067. Epub 2019 Aug 25.

Abstract

Background: Hidradenitis suppurativa (HS) is a debilitating skin condition whose pathogenesis is poorly understood, although interleukin (IL)-23 may play a role. IL-23 is also implicated in the pathogenesis of Crohn's disease (CD) and psoriasis, both of which can occur in patients with HS.

Case report: We present the case of a 28-year-old woman with HS, psoriasis, and CD, who was successfully treated with guselkumab after failing multiple other biologic agents.

Conclusion: Guselkumab represents a promising therapeutic option for recalcitrant HS patients with inflammatory comorbidities in which IL-23 plays a role.

Keywords: Guselkumab; IL-23; hidradenitis suppurativa.

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Biological Factors / therapeutic use
  • Crohn Disease / complications
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy*
  • Female
  • Hidradenitis Suppurativa / complications
  • Hidradenitis Suppurativa / diagnosis
  • Hidradenitis Suppurativa / drug therapy*
  • Hidradenitis Suppurativa / pathology
  • Humans
  • Interleukin-23 / immunology
  • Psoriasis / complications
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal, Humanized
  • Biological Factors
  • Interleukin-23
  • guselkumab